Ouchi, Kota
Takahashi, Shin
Sasaki, Keiju
Yoshida, Yuya
Taniguchi, Sakura
Kasahara, Yuki
Komine, Keigo
Imai, Hiroo
Saijo, Ken
Shirota, Hidekazu
Takahashi, Masanobu
Ishioka, Chikashi
Funding for this research was provided by:
Japan Agency for Medical Research and Development (grant number 11110018)
Article History
Accepted: 26 May 2024
First Online: 11 June 2024
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki. The protocol was approved by the ethics committees of all participating centers, and all patients provided written informed consent. In conducting this translational research, approval was also obtained from the Tohoku University Hospital Ethics Committee (Approval No. 2022–1-737).
: Dr. Kota Ouchi reports honoraria from Taiho, Eli Lilly, Asahi Kasei, and Merck, outside the submitted work; Dr. Shin Takahashi reports honoraria from Ono, Chugai, Yakult, Taiho, Asahi Kasei, Eisai, Eli Lilly, and Bristol-Myers Squib, outside the submitted work; Dr. Ken Saijo reports honoraria from Beyer, Eli Lilly, and Taiho, outside the submitted work; Prof. Chikashi Ishioka reports honoraria from, Taiho, Merck, Eli Lilly, Bristol, Daiichi, Nihon-Kayaku, Nihon Servier, M3, MSD, Novartis, AstraZeneca, Ono, Sanofi, Chugai, Terumo, Asahi Kasei, Pfizer, Byer, Incyte, Takeda, and Kyowa-Kirin, and research funding from Chugai, Asahi Kasei, Ono, Eli Lilly, Shionogi, Yakult, Otsuka, Sanofi, Merck, AstraZeneca, Bellinger, Yansen, Taiho, Takeda, Daiichi, Bayer, Nihon Kayaku, Tsumura, Kyowa-Kirin, Hitachi, Incyte, Ascent, Eizai, PRA Health Science, MSD, Sonia-Therapy, Novartis, and Riken Genesi. All remaining authors have declared no conflict of interest.